Educational strategies including pamphlets and recommendations from family physicians and support from a specialist can improve bone care in men with prostate cancer undergoing androgen deprivation therapy.
This video reviews studies investigating the use of germline clinical testing for breast cancer.
Survival disparities for black patients with ovarian, colon, and breast cancer and childhood ALL suggest a need for efforts toward improved screening and treatment adherence in this population.
This video highlights quality-of-life results from a large prospective study of men treated for breast cancer.
Acalabrutinib continues to yield high response rates in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Dual HER2 blockade with lapatinib and trastuzumab plus AI therapy was more effective than trastuzumab plus AI alone in HER2+, HR+ metastatic breast cancer.
A study found familial clustering of urothelial cancers, with increased risk of bladder cancer and others, in first- and second-degree relatives of these patients.
The FDA has approved nivolumab for the adjuvant treatment of melanoma; it showed superiority compared with the standard of care in this patient population.
Toxicities from buparlisib make it a poor option for patients with HR-positive, HER2-negative advanced breast cancer who progressed on mTOR inhibitor therapy.
Early disease progression for chronic lymphocytic leukemia was a robust prognostic factor for worse overall survival in patients treated with chemoimmunotherapy.